CLINICAL TRIALS PROFILE FOR PROMETHAZINE HYDROCHLORIDE PLAIN
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
All Clinical Trials for Promethazine Hydrochloride Plain
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00270777 ↗ | Improving Safety of Antivenom in People Bitten by Snakes | Completed | University of Kelaniya | Phase 4 | 2005-03-01 | A study to increase the safety of polyvalent antivenom involving 1000 patients in three centres: low dose adrenaline, promethazine, & hydrocortisone (alone and in combination) to prevent acute adverse reactions to antivenom in people bitten by snakes: randomised, double blind, placebo-controlled trial. |
| NCT00293215 ↗ | Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen | Terminated | Wyeth is now a wholly owned subsidiary of Pfizer | Phase 1 | 2006-02-01 | This was a Phase 1 dose-escalation study of CMD-193, a humanized monoclonal antibody linked to the toxin calicheamicin, in subjects with advanced tumors expressing the Lewis-Y antigen. The primary study objective was to determine the biodistribution and pharmacokinetics (PK) of 111-In-CMD-193 (i.e., CMD-193 tagged with a small amount of radioactive Indium [111-In]), with secondary objectives of determining changes in tumor metabolism and describing the antitumor responses to CMD-193. |
| NCT00293215 ↗ | Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen | Terminated | Ludwig Institute for Cancer Research | Phase 1 | 2006-02-01 | This was a Phase 1 dose-escalation study of CMD-193, a humanized monoclonal antibody linked to the toxin calicheamicin, in subjects with advanced tumors expressing the Lewis-Y antigen. The primary study objective was to determine the biodistribution and pharmacokinetics (PK) of 111-In-CMD-193 (i.e., CMD-193 tagged with a small amount of radioactive Indium [111-In]), with secondary objectives of determining changes in tumor metabolism and describing the antitumor responses to CMD-193. |
| NCT00429832 ↗ | A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department | Completed | GlaxoSmithKline | Phase 4 | 2003-10-01 | This was a trial comparing two commonly used medications for nausea and vomiting, ondansetron and promethazine, in the Emergency Department. |
| NCT00429832 ↗ | A RCT of Ondansetron and Promethazine in the Treatment of Nausea and Vomiting in the Emergency Department | Completed | University of New Mexico | Phase 4 | 2003-10-01 | This was a trial comparing two commonly used medications for nausea and vomiting, ondansetron and promethazine, in the Emergency Department. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Promethazine Hydrochloride Plain
Condition Name
Clinical Trial Locations for Promethazine Hydrochloride Plain
Trials by Country
Clinical Trial Progress for Promethazine Hydrochloride Plain
Clinical Trial Phase
Clinical Trial Sponsors for Promethazine Hydrochloride Plain
Sponsor Name
